2025 GU ASCO Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from GU ASCO 2025. Highlights in this video include: • CheckMate274: Adjuvant Nivolumab for high risk resected bladder cancer maintains DFS benefit with trend towards OS • NIAGARA: Perioperative Durvalumab with chemotherapy for muscle invasive bladder cancer associated with higher CR • INDUCT: Neoadjuvant Durvalumab with chemotherapy shows promise in upper tract urothelial carcinoma